The estimated Net Worth of Capital, Llc Boxer Asset Ma... is at least $78.8 Million dollars as of 17 March 2022. Capital Ma owns over 575,201 units of iTeos Therapeutics stock worth over $50,241,507 and over the last 7 years Capital sold ITOS stock worth over $28,597,835.
Sign up
Capital Ma ITOS stock SEC Form 4 insiders trading
Capital has made over 13 trades of the iTeos Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 575,201 units of ITOS stock worth $20,275,835 on 17 March 2022.
The largest trade Capital's ever made was buying 1,403,509 units of iTeos Therapeutics stock on 28 August 2020 worth over $20,000,003. On average, Capital trades about 398,496 units every 120 days since 2017. As of 17 March 2022 Capital still owns at least 3,142,058 units of iTeos Therapeutics stock.
You can see the complete history of Capital Ma stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at iTeos Therapeutics
Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol..., and Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.
What does iTeos Therapeutics do?
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
What does iTeos Therapeutics's logo look like?
Complete history of Capital Ma stock trades at Esperion Therapeutics, Mirati Therapeutics Inc, Odonate Therapeutics Inc, and iTeos Therapeutics
iTeos Therapeutics executives and stock owners
iTeos Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Michel Detheux Ph.D.,
Pres, CEO & Director -
Dr. Michel Detheux,
Pres, CEO & Director -
Dr. Joanne Jenkins Lager M.D.,
Chief Medical Officer -
Matthew Gall,
Chief Financial Officer -
Philippe Brantegem,
Vice-Pres of HR -
Ryan Baker,
Head of Investor Relations -
Matthew A. Call M.B.A.,
Chief Operating Officer -
David Feltquate,
Chief Medical Officer -
Bio Ventures 2014, L.P.Evni...,
-
Capital Management, L.P.Kol...,
-
Capital, Llc Boxer Asset Ma...,
-
Aaron I. Davis,
-
Ann D Rhoads,
-
Ansbert Gadicke,
Director -
Derek Di Rocco,
Director -
David Hallal,
-
Detlev Biniszkiewicz,
Director -
Capital, Llc Boxer Asset Ma...,
-
Hauwermeiren Timothy Van,
-
Ansbertubs Oncology Impact ...,
-
Bio Ventures 2014, L.P.Mpm ...,
-
Matthew Roden,
Director -
Matthew Call,
Chief Operating Officer -
Yvonne Mc Grath,
Chief Scientific Officer -
Joanne Jenkins Lager,
Chief Medical Officer -
Robert Iannone,
-
Capital Management, L.P.Ra ...,
-
Bio Ventures 2014, L.P.Evni...,
-
Bioventures 2018, L.P.Mpm B...,
-
Ansbertubs Oncology Impact ...,
-
Ansbertubs Oncology Impact ...,
-
Capital, Llc Boxer Asset Ma...,
-
Capital, Llc Boxer Asset Ma...,
-
David K Lee,
-
Michel Detheux,
Chief Executive Officer -
Matthew Gall,
Chief Financial Officer -
Jill De Simone,
-
Tony W Ho,